Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of tyrosine kinase inhibitor to treat diabetes

A tyrosine kinase and inhibitor technology, which is applied to the application of tyrosine kinase inhibitors in the treatment of diabetes, can solve the problems of shortening average lifespan, affecting blood sugar control, and decreasing quality of life.

Inactive Publication Date: 2006-06-28
罗伯特・佩尔・黑格奎斯特 +1
View PDF2 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite strict attention to maintaining a healthy diet, exercise regimen, and always injecting the right amount of insulin, many other factors can adversely affect a person's blood sugar control, including stress, hormonal changes, growth cycles, physical activity, medications, illness / infection and fatigue
Even with insulin, type 1 diabetes often results in a dramatic decline in quality of life and shortens lifespan by an average of 15 years

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of tyrosine kinase inhibitor to treat diabetes
  • Use of tyrosine kinase inhibitor to treat diabetes
  • Use of tyrosine kinase inhibitor to treat diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Example 1: Does compound I such as salt I protect against β-cell death and diabetes?

[0046] In the following examples, β-TC6 cells refer to beta-TC6 cells.

[0047] Insulin-dependent (type I) diabetes mellitus (IDDM) is a multifactorial autoimmune disease caused by the specific and progressive destruction of insulin-producing beta cells. The dysfunction and damage of β-cells are thought to be due to their interaction with islet-infiltrating cells (macrophages, CD4 + or CD8 + (NK)T-cells) and / or exposure to cytotoxic mediators produced by these cells, such as pro-inflammatory cytokines (IL-1, TNF-α, IFN-γ), free radicals, Fas ligand, TRAIL and perforin. Autoimmunity against β-cells can be triggered by environmental factors such as β-cell toxins, nutrients, stress, metabolic overload, viruses, etc. In type I diabetes, it is possible that β-cells actively participate in their own destruction by converting external death signals into internal apoptotic events. The ...

Embodiment 2

[0076] Example 2: 4-[(4-methyl-1-piperazin-1-ylmethyl)-N-[4-methyl-3-[[4-(3-pyridine Capsules of pyridyl)-2-pyrimidinyl]amino]phenyl]-benzamide methanesulfonate

[0077] Capsules containing 119.5 mg of Salt I corresponding to 100 mg of Compound I (free base) as active moiety were prepared with the following composition:

[0078] Salt I

[0079] The capsules are prepared by mixing the ingredients and filling the mixture into size 1 hard gelatin capsules.

Embodiment 3

[0080] Example 3: Mechanism of protection against β-cell death and diabetes induced by Compound I in vivo Research

[0081] background: Compound I is known to inhibit c-Abl, a ubiquitously expressed protein tyrosine kinase with a molecular weight of approximately 145 kDa. Under physiological conditions, c-Abl has been shown to be involved in the regulation of cytoskeletal functions such as migration and cell structure as well as cell cycle progression. However, when cells are exposed to different forms of stress, c-Abl becomes hyperactivated, which leads to cell cycle arrest and apoptosis.

[0082] Most recently obtained results: C-Abl is expressed in bTC-6 cells and isolated rat islets, and the use of pharmacologically active agent compound I to inhibit c-Abl activity against the expression of streptozotocin, pro-inflammatory cytokines or nitric oxide donors Protection against induced β-cell death. Compound I, such as salt I, is a selective inhibitor clinically used...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

The present invention relates to c-Abl-, PDGF-R- or c-kit-tyrosine kinase inhibitors such as 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3 -((4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide, bis(1H-2-indolyl)-1-methanone, AG1295, CT52923, RP-1776 , GFB-111, pyrrolo[3,4-c]-β-carboline-diketones, SU 102, AG1296, RPR101511A, CDP 860, Zvegf3, CP 673451, PD 170262, KI 6783, KN 1022, AG 13736 , CHIR 258, MLN 518, SU 11248, leflunomide or their pharmaceutically acceptable salts in the preparation of medicines for treating diabetes such as type I diabetes and type II diabetes.

Description

technical field [0001] The present invention relates to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-((4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl] - use of benzamide (hereinafter referred to as "compound I") or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition for the treatment of diabetes such as type I diabetes or type II diabetes, relating to compound I or its pharmaceutical The use of above acceptable salt in the treatment of diabetes such as type 1 diabetes or type 2 diabetes relates to the method of treating warm-blooded animals suffering from diabetes such as type 1 diabetes or type 2 diabetes, said warm-blooded animals include mammals, especially is a human, said method is achieved by administering to said animal in need of such treatment an effective dose of Compound I or a pharmaceutically acceptable salt thereof against said disease. Description of drawings [0002] figure 1 . Cytokine-induced NO production was not a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/506A61K31/404A61K31/42A61K31/437A61K31/47A61K31/498A61K31/517A61K31/519A61K38/12
Inventor 罗伯特·佩尔·黑格奎斯特尼尔斯·里查德·韦尔什
Owner 罗伯特・佩尔・黑格奎斯特
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com